% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pulte:143658,
      author       = {D. Pulte$^*$ and J. Weberpals$^*$ and L. Jansen$^*$ and H.
                      Brenner$^*$},
      title        = {{C}hanges in population-level survival for advanced solid
                      malignancies with new treatment options in the second decade
                      of the 21st century.},
      journal      = {Cancer},
      volume       = {125},
      number       = {15},
      issn         = {0008-543X},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2019-01232},
      pages        = {2656-2665},
      year         = {2019},
      abstract     = {Several new treatments that improve survival in clinical
                      trials have been developed for various solid malignancies in
                      advanced stages. The effect of these options on survival in
                      the general population is currently unknown.Cancers for
                      which 2 or more new treatment options have been approved by
                      the US Food and Drug Administration during the years 2009
                      through 2011 for the treatment of advanced disease were
                      identified, including adenocarcinoma of the lung, melanoma,
                      breast cancer, prostate cancer, and renal cell carcinoma.
                      Kaplan-Meier analysis was used to compare overall survival
                      for these conditions in the Surveillance, Epidemiology, and
                      End Results database for the periods 2007 to 2008, 2009 to
                      2010, and 2011 to 2012. Hazard ratios derived from adjusted,
                      shared frailty models for cancer-specific survival were
                      calculated as well for the years of diagnosis (2007-2008,
                      2009-2010, and 2011-2012).Two-year survival increased for
                      patients with advanced-stage lung adenocarcinoma
                      (+3.0 percentage points), melanoma (+3.4 percentage
                      points), and breast cancer (+2.7 percentage points). When
                      only patients aged 15 to 64 years were included, 2-year
                      survival for those with melanoma increased by
                      +6.7 percentage points. No change in survival was observed
                      for renal cell carcinoma. Decreases in the hazard ratio for
                      cancer-specific mortality were observed during the period
                      2011 to 2012 compared with 2007 to 2008 for lung
                      adenocarcinoma, melanoma, and breast cancer.Small increases
                      in 2-year survival were observed between the periods 2007 to
                      2008 and 2011 to 2012 for lung adenocarcinoma, melanoma, and
                      prostate cancer. Cancer-specific mortality decreased for
                      each of these cancers among patients who were diagnosed
                      between the periods 2007 to 2008 and 2011 to 2013. These
                      findings suggest that newer treatment options are beginning
                      to increase survival for stage IV cancers at the population
                      level.},
      cin          = {C070 / C120 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31095726},
      doi          = {10.1002/cncr.32160},
      url          = {https://inrepo02.dkfz.de/record/143658},
}